RNA methyltransferases Inhibitors
1 drugsAbout RNA methyltransferases
RNA methyltransferases catalyze the addition of methyl groups to RNA, regulating splicing, stability, and translation. These enzymes are emerging as drug targets due to their role in critical cellular processes.
Currently, there is no genetic evidence linking RNA methyltransferases to specific diseases. However, the success of ONUREG in oncology suggests that modulating RNA methylation pathways can impact disease progression.
ONUREG (Bristol-Myers Squibb) is the only FDA-approved drug targeting RNA methyltransferases, approved in 2020 for oncology indications. It is a small molecule, highlighting the feasibility of modulating these enzymes for therapeutic benefit.
Top RNA methyltransferases Drugs
Bristol-Myers Squibb is the only company with an approved drug targeting RNA methyltransferases.
The limited competitive landscape presents an opportunity for new entrants, but also indicates potential challenges in target validation.
RNA methyltransferases Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets RNA methyltransferases, using small molecule modality.
Explore alternative modalities like oligonucleotides or PROTACs to differentiate from existing approaches and expand therapeutic potential.
RNA methyltransferases Clinical Trials 549 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on RNA methyltransferases. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 254 | 81 | 75 | 93 | 52% |
| Phase 2 | 229 | 70 | 38 | 120 | 65% |
| Phase 3 | 59 | 17 | 13 | 29 | 57% |
| Phase 4 | 7 | 2 | 1 | 4 | 67% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
2 Phase 3 trials testing approved RNA methyltransferases drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting RNA methyltransferases. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
RNA methyltransferases Drug Approval Timeline (2020 - 2020)
The first and only drug, ONUREG, was approved in 2020.
The recent approval suggests growing interest, but further approvals are needed to confirm the target class's long-term viability.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 236 (84 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on RNA methyltransferases. A trial counts if an approved drug acting on RNA methyltransferases is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.